Bloomberg: Alexander's 15min Chart Triggers MACD Death Cross, Bearish Marubozu

According to the 15-minute chart for Alexander'S, a MACD Death Cross and a bearish Marubozu pattern were observed on August 28, 2025 at 11:15. These indicators suggest that the stock price is likely to continue its downward trajectory, as sellers have taken control of the market and bearish momentum is expected to persist.

Asieris Pharmaceuticals, a leading biopharmaceutical company, has released its 2025 Semi-Annual Report, highlighting sustained commercial growth and significant breakthroughs in its pipeline. The report, released on August 28, 2025, showcases the company's robust performance and innovative capabilities in the face of intense market competition [1].

Commercial Momentum

Asieris Pharmaceuticals reported a 61.8% year-over-year increase in operating revenue during the first half of 2025, reaching RMB 130 million. This growth is attributed to the successful implementation of Commercial Operation 2.0, which has strengthened the company's commercial framework and operational efficiency. The company's two marketed products, Ouyoubi and Dipaite, have shown strong sales, underscoring the company's improving commercialization capabilities [1].

Breakthrough Innovations

One of the standout achievements in the report is the progress of APL-1702, a first-in-class therapy for precancerous cervical lesions. APL-1702 is on track to become the world's first non-invasive therapy for high-grade squamous intraepithelial lesion (HSIL) of the cervix. The product has received strong endorsement from gynecology and pharmaceutical experts and is expected to address a significant unmet clinical need in China [1].

In urologic oncology, Hexvix®, China's first approved blue-light imaging agent for bladder cancer, has ushered in a new era of blue-light cystoscopy. The company is actively supporting the regulatory review of the SYSTEM BLUE blue-light cystoscopy system in China, with approval targeted by the end of 2025 [1].

Pipeline Advancements

Asieris Pharmaceuticals' pipeline continues to advance, with several candidates making solid progress and being highlighted at major international academic conferences. APL-2302, a potential best-in-class USP1 inhibitor, has received IND approval for Phase I/IIa trials in advanced solid tumors, while APL-2401, a potential best-in-class FGFR2/3 inhibitor, is in the IND-enabling phase. APL-1202, in combination with tislelizumab, has completed a Phase I/II trial as neoadjuvant therapy for muscle-invasive bladder cancer, demonstrating positive efficacy signals [1].

Financial Stability

As of the end of the reporting period, Asieris Pharmaceuticals holds approximately RMB 1.825 billion in cash, cash equivalents, and trading financial assets, providing a solid foundation for continued growth and innovation [1].

Conclusion

Asieris Pharmaceuticals' 2025 Semi-Annual Report underscores the company's strong performance and innovative capabilities. With sustained commercial momentum, breakthrough innovations in the pipeline, and a robust financial foundation, Asieris is well-positioned to continue driving growth and innovation in the biopharmaceutical sector.

References

[1] Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch. PR Newswire. Retrieved from https://www.morningstar.com/news/pr-newswire/20250828cn61079/asieris-pharmaceuticals-releases-2025-semi-annual-report-with-sustained-commercial-momentum-and-breakthrough-innovation-poised-for-launch